Benitec Biopharma Inc.
BNTC
$14.10
$0.322.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -100.00% |
| SG&A Expenses | 562.13% | 166.67% | 93.97% | 42.23% | 48.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 209.59% | 146.03% | 24.30% | -1.41% | 21.75% |
| Operating Income | -209.59% | -146.03% | -24.30% | 1.41% | -21.93% |
| Income Before Tax | -242.10% | -118.60% | -8.22% | 15.03% | -1.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -242.10% | -118.60% | -8.22% | 15.03% | -1.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -242.10% | -118.60% | -8.22% | 15.03% | -1.27% |
| EBIT | -209.59% | -146.03% | -24.30% | 1.41% | -21.93% |
| EBITDA | -210.79% | -147.21% | -24.40% | 1.52% | -21.93% |
| EPS Basic | -114.61% | -3.50% | 87.37% | 84.40% | 93.55% |
| Normalized Basic EPS | -114.71% | -3.55% | 87.37% | 82.78% | 93.55% |
| EPS Diluted | -114.61% | -3.50% | 87.37% | 84.40% | 93.55% |
| Normalized Diluted EPS | -114.71% | -3.55% | 87.37% | 82.78% | 93.55% |
| Average Basic Shares Outstanding | 59.36% | 111.14% | 756.86% | 393.46% | 1,470.05% |
| Average Diluted Shares Outstanding | 59.36% | 111.14% | 756.86% | 393.46% | 1,470.05% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |